218 related articles for article (PubMed ID: 23571420)
1. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.
Lukas SE; Lowen SB; Lindsey KP; Conn N; Tartarini W; Rodolico J; Mallya G; Palmer C; Penetar DM
Neuroimage; 2013 Sep; 78():176-85. PubMed ID: 23571420
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
[TBL] [Abstract][Full Text] [Related]
4. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
Lee JD; Grossman E; Huben L; Manseau M; McNeely J; Rotrosen J; Stevens D; Gourevitch MN
J Subst Abuse Treat; 2012 Dec; 43(4):458-62. PubMed ID: 22985676
[TBL] [Abstract][Full Text] [Related]
5. Early treatment response in alcohol dependence with extended-release naltrexone.
Ciraulo DA; Dong Q; Silverman BL; Gastfriend DR; Pettinati HM
J Clin Psychiatry; 2008 Feb; 69(2):190-5. PubMed ID: 18348601
[TBL] [Abstract][Full Text] [Related]
6. Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON).
Malone M; McDonald R; Vittitow A; Chen J; Obi R; Schatz D; Tofighi B; Garment A; Kermack A; Goldfeld K; Gold H; Laska E; Rotrosen J; Lee JD
Contemp Clin Trials; 2019 Jun; 81():102-109. PubMed ID: 30986535
[TBL] [Abstract][Full Text] [Related]
7. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular extended-release naltrexone: current evidence.
Gastfriend DR
Ann N Y Acad Sci; 2011 Jan; 1216():144-66. PubMed ID: 21272018
[TBL] [Abstract][Full Text] [Related]
9. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
[TBL] [Abstract][Full Text] [Related]
10. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
Pettinati HM; Gastfriend DR; Dong Q; Kranzler HR; O'Malley SS
Alcohol Clin Exp Res; 2009 Feb; 33(2):350-6. PubMed ID: 19053979
[TBL] [Abstract][Full Text] [Related]
11. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.
Lapham S; Forman R; Alexander M; Illeperuma A; Bohn MJ
J Subst Abuse Treat; 2009 Jan; 36(1):1-6. PubMed ID: 18775624
[TBL] [Abstract][Full Text] [Related]
12. Extended-release naltrexone for treatment of alcohol dependence in primary care.
Lee JD; Grossman E; DiRocco D; Truncali A; Hanley K; Stevens D; Rotrosen J; Gourevitch MN
J Subst Abuse Treat; 2010 Jul; 39(1):14-21. PubMed ID: 20363090
[TBL] [Abstract][Full Text] [Related]
13. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community: Results From a Double-Blind, Placebo-Controlled Trial.
Springer SA; Di Paola A; Barbour R; Azar MM; Altice FL
J Acquir Immune Defic Syndr; 2018 Sep; 79(1):92-100. PubMed ID: 29781884
[TBL] [Abstract][Full Text] [Related]
14. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
15. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
Jarvis BP; Holtyn AF; DeFulio A; Koffarnus MN; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Drug Alcohol Depend; 2019 Apr; 197():220-227. PubMed ID: 30852374
[TBL] [Abstract][Full Text] [Related]
16. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
17. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
[TBL] [Abstract][Full Text] [Related]
18. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
Lapham SC; McMillan GP
J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
[TBL] [Abstract][Full Text] [Related]
19. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
[TBL] [Abstract][Full Text] [Related]
20. Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone.
Bach P; Weil G; Pompili E; Hoffmann S; Hermann D; Vollstädt-Klein S; Mann K; Perez-Ramirez U; Moratal D; Canals S; Dursun SM; Greenshaw AJ; Kirsch P; Kiefer F; Sommer WH
Addict Biol; 2020 Jan; 25(1):e12717. PubMed ID: 30748046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
